The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
In terms of private investments, 2020 was the year of the liquid biopsy.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
It takes more than a pandemic to stop medical device companies merging.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
The pandemic provided the best and worst of times for smid-cap medtechs.
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.